BRPI0812875B8 - " método in vitro para indentificar se ou não um indivíduo está sob risco de desenvolvimento de sépsis severa, e, kit de teste - Google Patents

" método in vitro para indentificar se ou não um indivíduo está sob risco de desenvolvimento de sépsis severa, e, kit de teste

Info

Publication number
BRPI0812875B8
BRPI0812875B8 BRPI0812875A BRPI0812875A BRPI0812875B8 BR PI0812875 B8 BRPI0812875 B8 BR PI0812875B8 BR PI0812875 A BRPI0812875 A BR PI0812875A BR PI0812875 A BRPI0812875 A BR PI0812875A BR PI0812875 B8 BRPI0812875 B8 BR PI0812875B8
Authority
BR
Brazil
Prior art keywords
individual
risk
severe sepsis
test kit
identify whether
Prior art date
Application number
BRPI0812875A
Other languages
English (en)
Inventor
Björck Lars
Christensson Bertil
Herwald Heiko
Linder Adam
Äkesson Per
Original Assignee
Hansa Medical Ab
Hansa Biopharma AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38331957&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0812875(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hansa Medical Ab, Hansa Biopharma AB filed Critical Hansa Medical Ab
Publication of BRPI0812875A2 publication Critical patent/BRPI0812875A2/pt
Publication of BRPI0812875B1 publication Critical patent/BRPI0812875B1/pt
Publication of BRPI0812875B8 publication Critical patent/BRPI0812875B8/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Electrotherapy Devices (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

MÉTODO IN VITRO PARA IDENTIFICAR SE OU NÃO UM INDIVÍDUO ESTÁ SOB RISCO DE DESENVOLVIMENTO DE SÉPSIS SEVERA, E, KIT DE TESTE. Tem sido demonstrado que o nível de HBP aumenta em indivíduos que subseguentemente desenvolvem sépsis severa. Conformemente, o nível de HBP, a razão de HBP/WBC ou a razão de HBP/NC em um indivíduo podem ser usados para determinar se ou não um indivíduo está sob risco de desenvolvimento de sépsis severa.
BRPI0812875A 2007-06-12 2008-06-12 " método in vitro para indentificar se ou não um indivíduo está sob risco de desenvolvimento de sépsis severa, e, kit de teste BRPI0812875B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0711327.7 2007-06-12
GBGB0711327.7A GB0711327D0 (en) 2007-06-12 2007-06-12 Diagnostic method
PCT/EP2008/004743 WO2008151808A1 (en) 2007-06-12 2008-06-12 Diagnostic method

Publications (3)

Publication Number Publication Date
BRPI0812875A2 BRPI0812875A2 (pt) 2014-12-09
BRPI0812875B1 BRPI0812875B1 (pt) 2017-12-05
BRPI0812875B8 true BRPI0812875B8 (pt) 2022-07-12

Family

ID=38331957

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0812875A BRPI0812875B8 (pt) 2007-06-12 2008-06-12 " método in vitro para indentificar se ou não um indivíduo está sob risco de desenvolvimento de sépsis severa, e, kit de teste

Country Status (16)

Country Link
US (3) US8518648B2 (pt)
EP (1) EP2129391B1 (pt)
JP (1) JP5166522B2 (pt)
KR (1) KR101563997B1 (pt)
CN (2) CN101687023B (pt)
AT (1) ATE548050T1 (pt)
AU (1) AU2008261252B2 (pt)
BR (1) BRPI0812875B8 (pt)
CA (1) CA2690067C (pt)
DK (1) DK2129391T3 (pt)
ES (1) ES2380875T3 (pt)
GB (1) GB0711327D0 (pt)
PL (1) PL2129391T3 (pt)
PT (1) PT2129391E (pt)
SI (1) SI2129391T1 (pt)
WO (1) WO2008151808A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0711327D0 (en) 2007-06-12 2007-07-25 Hansa Medical Ab Diagnostic method
US20100240049A1 (en) 2009-01-16 2010-09-23 Cepheid Methods of Detecting Cervical Cancer
JP5488885B2 (ja) * 2009-10-28 2014-05-14 国立大学法人 東京大学 感染症の疾患マーカー
GB201016161D0 (en) 2010-09-24 2010-11-10 Hansa Medical Ab Diagnostic method
EP2643483A4 (en) * 2010-11-26 2014-04-30 Immunexpress Pty Ltd DIAGNOSTIC AND / OR SCREENING APPROPRIATIONS AND USES THEREFOR
GB201102108D0 (en) * 2011-02-07 2011-03-23 Hansa Medical Ab Diagnostic method
CA2848873A1 (en) * 2011-09-16 2013-03-21 Cepheid Methods of detecting sepsis
US10260111B1 (en) 2014-01-20 2019-04-16 Brett Eric Etchebarne Method of detecting sepsis-related microorganisms and detecting antibiotic-resistant sepsis-related microorganisms in a fluid sample
US10761093B2 (en) 2014-10-09 2020-09-01 Texas Tech University System Microdevice for cell separation utilizing activation phenotype
CN109541235A (zh) * 2018-08-19 2019-03-29 重庆早柒天生物科技股份有限公司 肝素结合蛋白和降钙素原二联检测试剂盒及其制备方法
EP3960758A4 (en) 2019-04-24 2023-02-15 Japanese Foundation For Cancer Research PROCEDURE FOR DETECTING CANCER AND DETECTION REAGENT
CN111208305B (zh) * 2020-02-16 2023-04-25 重庆翼锋生物科技有限公司 Hbp和pct在败血症诊断试剂制备中的用途
CN111951963B (zh) 2020-07-30 2022-09-02 中翰盛泰生物技术股份有限公司 Hbp在covid-19患者的预后风险预警中的应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5627262A (en) * 1989-07-05 1997-05-06 The Board Of Regents Of The University Of Oklahoma Method and composition for the treatment of septic shock
US5962241A (en) * 1989-07-28 1999-10-05 The University Of Arizona Monoclonal antibody detection of proteins on sperm related to fertility
US5314804A (en) * 1992-03-24 1994-05-24 Serim Research Corporation Test for Helicobacter pylori
AU703963B2 (en) * 1994-04-21 1999-04-01 Leukotech A/S Heparin-binding protein for the treatment of sepsis and processes for its preparation
US5976536A (en) 1995-08-09 1999-11-02 Emory University Neisseria mutants, lipooligosaccharides and immunogenic compositions
US5778895A (en) 1997-01-29 1998-07-14 Uab Research Foundation Method of discriminating bacterial from aseptic meningitis
US6303321B1 (en) * 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
AU2003220034A1 (en) * 2002-03-08 2003-09-22 Heloise, Anne, Pereira, Ph. D. An early detection marker for chronic inflammatory associated diseases
US7655480B2 (en) * 2002-03-08 2010-02-02 The Board Of Regents Of The University Of Oklahoma Method for predicting sepsis or an acute infectious inflammatory response
EP1581556A2 (en) 2002-08-15 2005-10-05 Leukotech A/S Bactericidal, anti-apoptotic, pro-inflammatory and anti-inflammatory peptides of heparin-binding protein (hbp)
JP2006515227A (ja) * 2003-02-24 2006-05-25 ジーティーシー バイオセラピューティックス インコーポレイテッド 十字流濾過の方法およびそのための装置
US7191068B2 (en) * 2003-03-25 2007-03-13 Proteogenix, Inc. Proteomic analysis of biological fluids
EP1638530A2 (en) * 2003-06-20 2006-03-29 Royer Biomedical, INC. Drug polymer complexes
WO2005028512A1 (en) 2003-09-19 2005-03-31 Leukotech A/S Pro-inflammatory and anti-inflammatory antibodies against the heparin-binding protein (hbp)
US20050196817A1 (en) * 2004-01-20 2005-09-08 Molecular Staging Inc. Biomarkers for sepsis
BRPI0609302A2 (pt) * 2005-04-15 2011-10-11 Becton Dickinson Co métodos para prever o desenvolvimento de sepse e para diagnosticar sepse em um indivìduo a ser testado, microarranjo, kit para prever o desenvolvimento de sepse em um indivìduo a ser testado, produto de programa de computador, computador, sistema de computador para determinar se um indivìduo é susceptìvel de desenvolver sepse, sinal digital embutido em uma onda portadora, e, interface gráfica de usuário para determinar se um indivìduo é susceptìvel de desenvolver sepse
AU2006299417A1 (en) * 2005-10-03 2007-04-12 Biosite Incorporated Methods and compositions for diagnosis and/or prognosis in Systemic Inflammatory Response Syndromes
FR2894675B1 (fr) 2005-12-14 2008-06-27 Assist Publ Hopitaux De Paris Distinction des meningites bacteriennes et virales
GB0711327D0 (en) 2007-06-12 2007-07-25 Hansa Medical Ab Diagnostic method
GB201016161D0 (en) 2010-09-24 2010-11-10 Hansa Medical Ab Diagnostic method
GB201102108D0 (en) 2011-02-07 2011-03-23 Hansa Medical Ab Diagnostic method

Also Published As

Publication number Publication date
US20100305185A1 (en) 2010-12-02
CA2690067A1 (en) 2008-12-18
BRPI0812875A2 (pt) 2014-12-09
ES2380875T3 (es) 2012-05-21
JP2010529468A (ja) 2010-08-26
WO2008151808A1 (en) 2008-12-18
US8518648B2 (en) 2013-08-27
BRPI0812875B1 (pt) 2017-12-05
CA2690067C (en) 2023-09-19
PT2129391E (pt) 2012-06-06
US20130252347A1 (en) 2013-09-26
CN101687023B (zh) 2016-04-20
ATE548050T1 (de) 2012-03-15
US20140187503A1 (en) 2014-07-03
EP2129391B1 (en) 2012-03-07
CN103543271A (zh) 2014-01-29
US9784741B2 (en) 2017-10-10
DK2129391T3 (da) 2012-06-11
KR101563997B1 (ko) 2015-10-28
AU2008261252A1 (en) 2008-12-18
KR20100021578A (ko) 2010-02-25
AU2008261252B2 (en) 2013-03-14
GB0711327D0 (en) 2007-07-25
SI2129391T1 (sl) 2012-07-31
CN101687023A (zh) 2010-03-31
EP2129391A1 (en) 2009-12-09
JP5166522B2 (ja) 2013-03-21
PL2129391T3 (pl) 2012-09-28

Similar Documents

Publication Publication Date Title
BRPI0812875B8 (pt) " método in vitro para indentificar se ou não um indivíduo está sob risco de desenvolvimento de sépsis severa, e, kit de teste
BR112012031071A2 (pt) 8-proteínas de ligação à il-1
WO2006117596A8 (en) Nucleic acid probes and nucleic acid analog probes
WO2008070865A3 (en) Materials and methods for efficient and accurate detection of analytes
HK1114883A1 (en) Skin aging marker and technique for use thereof
WO2008021290A8 (en) Organ-specific proteins and methods of their use
CO6410314A2 (es) Proteínas de unión a il-17
NZ701807A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
MA30922B1 (fr) Anticorps d'agonistes de trkb et leurs utilisations
EA201992748A1 (ru) Диагностические анализы для обнаружения, количественного определения и/или отслеживания микроорганизмов и других аналитов
EA201390638A1 (ru) Обогащение и идентификация фетальных клеток в материнской крови и лиганды для такого применения
EA201391627A1 (ru) Анализ на наличие лизилоксидазоподобных белков 2 и способы его применения
WO2005031005A3 (en) Compositions, methods and kits for determining the presence of trichomonas vaginalis in a test sample
HK1149956A1 (en) Method of assessing colorectal cancer from a stool sample by use of the marker combination calprotectin and hemoglobin/haptoglobin complex
FR2900936B1 (fr) Procede et methodes de detection de la maladie d'alzheimer
HK1133295A1 (en) Use of protein s100a12 as a marker for colorectal cancer s100a12
GB201014837D0 (en) Biomarker signatures and uses thereof
ATE514081T1 (de) T-zellen-testverfahren
DE602006015727D1 (de) Verfahren zur messung von plasmaspiegeln von pentraxin ptx3
ATE420374T1 (de) Automatisches testsystem mit leicht modifizierter software
EP3990919C0 (en) METHOD AND KIT FOR MEASURING ANALYTES IN TWO-COMPONENT SYSTEMS AND USES THEREOF
ATE467128T1 (de) Kolloidale metallkonjugate
WO2006066917A3 (en) Use of asc as a marker for colorectal cancer
WO2009108170A3 (en) Compositions and methods for determining immune status
WO2017211893A8 (en) Biomarker signatures of systemic lupus erythematosus and uses thereof

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B25D Requested change of name of applicant approved